Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration
NCT ID: NCT01745731
Last Updated: 2015-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
13 participants
INTERVENTIONAL
2011-03-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients will receive concomitant basic pharmacological treatment for maintaining liver function.
All patients will be equally medically treated. The hypothetic test is to propose mononuclear cells from the bone marrow infused in the territory hepatic portal remaining segments (II and III) to be performed while contralateral portal embolization provides progenitor cells hepatic regenerative capacity that would shorten the time of liver regeneration and increase residual volume, facilitating the realization of an extended hepatectomy with greater assurance of maintaining proper residual function and adequate surgical margins.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study population will consist of a total of 65 patients divided into two groups:
Study group: patients with hepatic space occupying lesion requiring an extended hepatic resection to those who are undergoing preoperative embolization segments portal intraportal affections and application of bone marrow cells.
Control group: patients with hepatic space occupying lesion that require an extended liver resection and who were performed preoperatively embolization portal of the affected segments.
The distribution of cases / controls will be 1/1. Patients in study group before surgery as well as portal embolization of the affected by the injury, will receive the experimental treatment being tested. Autologous bone marrow will be extracted by aspiration of the iliac crest under local anesthesia, and then the mononuclear cells (mo-MNCs) will be separated by density gradient centrifugation on Ficoll by an automatic procedure in the Laboratory for Cell Therapy.
In the control group patients will be held an embolization of liver segments in which are located the lesion.
It is estimated that the inclusion period is approximately 24 months plus the follow-up of each patient twelve months. Thus the total duration of the study will be about thirty-six months from the entry of the first patient until the end of the monitoring period of the last patient included.
The main objective is to evaluate the safety and feasibility of autologous bone marrow mononuclear cells as autologous liver regeneration enhancer, administered intraportal before surgery in patients with liver space occupying lesion that require extended hepatic resection and in which the residual liver volume is insufficient to ensure liver function and safety margins required after the resection.
Secondary objectives:
* Complications from regenerative therapy and / or study procedures.
* Increased volume obtained after applying the procedures of liver regeneration after surgery.
* The percentage of resections that has allowed liver regeneration.
* The liver functional status after surgery.
* The resection margins free of tumor.
Evaluation Methods:
Radiological assessment of liver volumes. Analytical evaluation of markers of regeneration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
Control
Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \- Standard analytical parameters, defined by:
* Leukocytes ≥ 3000
* Neutrophils ≥ 1500
* Platelets ≥ 100,000
* Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 1.5 standard range institution
* creatinine ≤ 1.5 mg / dl
3. \- Patients with liver space occupying lesion (LOE) that require extended hepatic resection.
Patient selection should be cautious, covering basically 5 types of liver damage which must be submitted prior to liver volumetry:
* Metastatic Disease subsidiary right hepatectomy extended to segment IV
* Metastatic Disease subsidiary right hepatectomy with suspected diseased liver (neoadjuvant chemotherapy) (in cases of doubt may be used liver function test "indocyanine green")
* Bilobar liver metastases with multiple nodules in the right lobe and more than 3 nodules greater than 30 mm in the left hepatic lobe (LHI) will perform lumpectomies the LHI + right portal branch ligation (or postoperative percutaneous embolization) in order to make right hepatectomy 4-6 weeks ("two stage" surgery)
* Subsidiary Hepatocarcinoma extended right hepatectomy
* Liver Injury benign / malignant (Hemangiomas, hydatid cysts or liver tumors / primary bile hepatoblastoma), which by extension threatens the viability of the remaining liver tissue.
4 - Patients give their written informed consent for participation in the study and provide sufficient guarantees adherence to protocol according to the opinion of the investigator in charge of the patient care.
Exclusion Criteria
2. Patients with uncontrolled hypertension.
3. Severe heart failure (NYHA IV).
4. Patients with malignant ventricular arrhythmias or unstable angina.
5. Diagnosis of deep vein thrombosis in the previous 3 months.
6. Adjunctive therapy including hyperbaric oxygen, vasoactive substances, agents or angiogenesis inhibitors against Cox-II.
7. BMI\> 40 kg/m2.
8. Patients with alcoholic with active alcoholism.
9. Proliferative retinopathy.
10. Concomitant disease that reduces life expectancy to less than a year.
11. Difficulty in monitoring.
12. Heart failure or ejection fraction (EF) \<30%.
13. Stroke or myocardial infarction within the last 3 months.
14. Pregnant women or women of childbearing age who do not have adequate contraception.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iniciativa Andaluza en Terapias Avanzadas
OTHER
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francisco Javier Padillo, MD
Role: PRINCIPAL_INVESTIGATOR
Head of General and Digestive Surgery, University Hospital Virgen del Rocio
Antonio Galindo, MD
Role: PRINCIPAL_INVESTIGATOR
Head of General and Digestive Surgery, University Hospital Nuestra Señora de Valme
Daniel Garrote, MD
Role: PRINCIPAL_INVESTIGATOR
Section Chief of General Surgery, University Hospital Virgen de las Nieves
Sebastian Rufian, MD
Role: PRINCIPAL_INVESTIGATOR
Head of General and Digestive Surgery, University Hospital Reina Sofia
Francisco Javier Padillo, MD
Role: STUDY_CHAIR
Head of General and Digestive Surgery, University Hospital Virgen del Rocio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Virgen del Rocio
Seville, Sevilla, Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Andalusian Molecular Biology and Regenerative Medicine Centre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-017793-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CMMo/RH/2009
Identifier Type: -
Identifier Source: org_study_id